At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 1, 2026 at 07:15 ET
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's disease dementia, a major label expansion for an already-approved MDD drug. This addresses a large, underserved patient population (up to 76% of >7M Alzheimer's patients) with no approved treatment, creating a significant commercial opportunity.
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.
- Alzheimer's disease affects >7 million people in the U.S., with agitation reported in up to 76% of patients.
- AUVELITY was initially approved for MDD in 2022 and is protected by a robust patent estate extending to at least 2043.
- The approval addresses a condition with no currently approved treatment, representing a significant unmet medical need.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access